IND 37 - Next Generation MRI Contrast Agents: Lower Dose, Same Diagnostic Confidence

With over 800 million administrations globally, gadolinium-based contrast agents (GBCAs) are crucial for enhancing diagnostic imaging across various indications. As the focus shifts to using only the dose that is necessary to achieve diagnostic confidence for patients, next-generation high-relaxivity low-dose macrocyclic GBCAs, like the investigational gadoquatrane*, offer a promising opportunity in contrast-enhanced MRI. These innovative agents enhance relaxivity, allowing for lower doses while maintaining optimal image quality.

Join us to explore the potential of gadoquatrane* in MRI, demonstrated during Phase 3 clinical trials in the central nervous system, body organs, and pediatric imaging. Our expert speakers will discuss the efficacy and safety profile of this high-relaxivity, low-dose agent. In addition, they will explore considerations for adoption of high-relaxivity, low dose agents in practice.

LEARNING OBJECTIVES:
Understand the latest innovations in next generation GBCAs, and the approaches to achieving a low-dose, specifically for gadoquatrane*.
Dive deep into the efficacy and safety profile, and clinical cases using gadoquatrane*, including updates from Phase 3 clinical trials in CNS, body, and pediatric MR imaging.
Explore recently published guidelines and recommendations for contrast-enhanced MRI using next generation low-dose GBCAs.
Discuss the practical adoption of next generation low-dose agents and assess their potential in clinical practice.

*gadoquatrane is an investigational macrocyclic GBCA which has completed Phase III clinical development, however, is unlicensed and at the time of writing has not yet been fully assessed by any Health Authority in Europe, or globally.